Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
OPKO Health, Inc. (NASDAQ: OPK) has established a joint venture with LeaderMed Health Group to develop two clinical-stage drug products for the Asian market. The venture will focus on OPK88003, targeting obesity and diabetes, and Factor VIIa-CTP for hemophilia. OPKO retains a 47% stake in the venture after receiving a $1 million upfront payment and reimbursement for clinical trial materials. LeaderMed will manage funding, contributing $11 million for a 53% interest. This collaboration aims to enhance OPKO's market presence in Greater China and other Asian territories.
OPKO Health, Inc. (NASDAQ: OPK) has completed enrollment for the Phase 2 trial of RAYALDEE® for treating mild-to-moderate COVID-19, exceeding the expected total with 171 participants. The randomized study will assess RAYALDEE's efficacy in raising serum 25-hydroxyvitamin D levels and the resolution time of COVID-19 symptoms. Primary endpoints include achieving the targeted vitamin D levels, while secondary endpoints focus on hospitalization rates and overall illness severity. Topline results are anticipated later this year.
OPKO Health, Inc. (NASDAQ: OPK) has announced participation in two significant virtual investor conferences in September 2021. The 14th Annual Barrington Research Fall Conference will take place on September 9, 2021, featuring one-on-one and small-group meetings with management. Subsequently, OPKO will attend the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, where management will engage in a fireside chat and additional investor meetings. A recording of the fireside chat will be available on OPKO's website starting September 13.
Rite Aid (NYSE: RAD) and BioReference, an OPKO Health company (NASDAQ: OPK), will provide free COVID-19 testing for New York State public school students ahead of the 2021-2022 school year. This ‘Back to School’ program allows students aged 4-17 to access RT-PCR tests at 115 Rite Aid drive-thru locations. Testing is voluntary, with results delivered digitally to parents. Governor Kathy Hochul emphasized the program's importance in combating the Delta variant and ensuring safe school environments. The initiative aligns with federal efforts to expand school testing.
BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche. This acquisition enhances BioReference's non-invasive prenatal screening (NIPS) capabilities, particularly through the Harmony Prenatal Test, which is widely used and has been performed on over 1.5 million patients. The transaction aligns with BioReference's 40-year commitment to women's health and aims to improve prenatal testing accessibility, impacting millions of pregnancies annually.
Summary not available.
OPKO Health, Inc. (NASDAQ: OPK) will report its Q2 2021 operating and financial results on July 29, 2021, after U.S. market close. The company will provide a detailed business update during a conference call at 4:30 PM ET on the same day. Interested parties can pre-register for the call or access it via the provided webcast link. OPKO focuses on biopharmaceuticals and diagnostics, aiming to lead in rapidly growing markets through innovative technologies. Additional details and a replay will be available on OPKO's website.
OPKO Health, Inc. (NASDAQ: OPK) has entered into a worldwide agreement with CAMP4 Therapeutics for developing therapeutics based on the AntagoNAT technology. This agreement marks a significant step in advancing OPKO's lead compound for Dravet syndrome into clinical trials. OPKO will receive an upfront payment and is eligible for up to $93.5 million in milestone payments, plus royalties on product sales. The collaboration not only enhances OPKO’s focus on drug development but also validates its proprietary technology.
OPKO Health, Inc. (NASDAQ: OPK) will participate in the virtual Ladenburg Thalmann Healthcare Conference on July 13-14, 2021. Management will engage in a fireside chat on July 13 at 8:30 a.m. Eastern Time and will conduct one-on-one virtual meetings with investors throughout the day. The fireside chat will be archived in OPKO Health's Investors section on their website for future viewing. OPKO is focused on establishing a strong market position in biopharmaceuticals and diagnostics, leveraging its innovative technologies.
OPKO Health, Inc. (NASDAQ: OPK) has appointed Katherine Stueland as President and CEO of its subsidiary, GeneDx, Inc. Stueland, previously a Chief Commercial Officer at Invitae Corporation, brings two decades of leadership in the healthcare industry. Under her guidance, GeneDx aims to leverage genomic information to enhance patient care, emphasizing access to diagnostics for rare genetic disorders. The company has been a leading player in genomics for over 20 years, offering a wide array of genetic testing services.